Artivion, Inc. (AORT)

Artivion's stock price was $25.410 as of May 8, 2026, down 28.26% from its previous closing price. The stock is down 44.29% year-to-date. In Q1 2026, Artivion reported revenues of $116.3 million, an 18% increase year-over-year on a GAAP basis. The company announced the acquisition of Endospan Ltd. for $135 million. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million. Analyst actions have been mixed, with a consensus "Moderate Buy" rating and an average price target of $47.83. In the past three months, Artivion insiders have sold $4,977,158.00 in company stock.

Historically, demand for Artivion's cardiac and vascular preservation services has shown seasonality, with peak demand typically occurring in the third quarter. This seasonality is reportedly lessening as the company distributes a higher percentage of its tissues for use in adult populations. The first quarter is typically the seasonally lowest free cash flow quarter.

Artivion, Inc., formerly CryoLife Inc., specializes in medical devices and implantable human tissues for cardiac and vascular surgical procedures, particularly for aortic disease. Its major product families include aortic stent grafts, surgical sealants, On-X mechanical heart valves, implantable cardiac and vascular human tissues (allografts), and other products like PhotoFix bovine surgical patches and Chord-X ePTFE sutures.

Artivion has a significant international presence, marketing and selling its products in over 100 countries worldwide. Key geographic regions include North America, Europe, Middle East and Africa (EMEA), Asia-Pacific, and Latin America. Manufacturing facilities are located in Atlanta, Georgia; Austin, Texas; and Hechingen, Germany. Sales and distribution offices are maintained in various countries across Europe, Asia, and South America.

Artivion generally maintains a positive brand reputation within its specialized field and is recognized as a leader in aortic repair solutions. A cybersecurity incident in late 2024 could have impacted its reputation, but tissue processing revenues have recovered. The recent FDA approval for the NEXUS Aortic Arch System is a positive regulatory win.

Artivion, Inc. is primarily owned by institutional shareholders, who hold approximately 86.37% to 90.09% of the company's stock. Individual investors account for a smaller portion, around 6.76%. Insiders hold about 6.30% to 22.56% of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Morgan Stanley. The largest individual shareholder is Oss Capital Management, owning 8.18% of the company.